Monograph Details
|
|
Pain & Pyrexia
> Migraine and headache
|
|
ZOMIG-ZMT |
| Manufacturer |
|
AstraZeneca Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Selective 5-HT1B/1D receptor agonist. |
| Generic Name |
|
Zolmitriptan 2.5mg, 5mg; orally-disintegrating tabs; orange flavor; contains phenylalanine. |
| Also |
• ZOMIG
• ZOMIG NASAL SPRAY
|
| Indications |
|
Acute treatment of migraine. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
≥18yrs: Initially 2.5mg or lower once. If headache returns, may repeat after 2 hrs; max 10mg/day. Reevaluate if no response after 1st dose. The safety of treating an average of more than 3 headaches in a 30-day period has not been established. Hepatic impairment: use low dose. ZMT: dissolve on tongue and swallow without water. |
| Contraindications |
|
Ischemic heart disease (angina pectoris, history of MI, documented silent ischemia). Coronary artery vasospasm (eg, Prinzmetal's angina). Uncontrolled hypertension. Other significant cardiovascular disease. Basilar or hemiplegic migraine. Within 24 hours of ergot-type drugs or other 5-HT1 agonists. During or within 2 weeks after discontinuing MAOIs (type A). |
| Precautions |
|
Confirm diagnosis. Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders: not recommended. Exclude underlying cardiovascular disease, supervise 1st dose, and consider monitoring ECG in patients with likelihood of unrecognized coronary disease (eg, postmenopausal women, men over age 40, hypertension, hypercholesterolemia, obesity, diabetes, smokers, strong family history). Monitor cardiovascular function in long-term intermittent use. Cerebrovascular events (eg, stroke, TIA), peripheral vascular or colonic ischemia following other 5-HT1 agonists. Hepatic dysfunction (monitor BP). Elderly. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
MAOIs (type A), methysergide, other ergotamines, other 5-HT1 agonists: see Contraindications. Serotonin syndrome with SSRIs (eg, fluoxetine, fluvoxamine, paroxetine, sertraline). Absorption and half-life increased by cimetidine. |
| Adverse Reactions |
|
Paresthesia, asthenia, nausea, dizziness, pain, chest/jaw/throat tightness or heaviness, somnolence, warm feeling; rare: serious cardiac events. Nasal spray: also taste disturbances, local reactions. |
| How Supplied |
Tabs, ZMT tabs 2.5mg—6
Tabs, ZMT tabs 5mg—3
Single-dose sprayer—6 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
